Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Account Payables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Account Payables for 11 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 384.61% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 11.96% year-over-year, with the annual reading at $6.0 million for FY2025, 11.96% down from the prior year.
  • Change in Account Payables for Q4 2025 was $7.0 million at Intellia Therapeutics, up from $3.5 million in the prior quarter.
  • The five-year high for Change in Account Payables was $7.0 million in Q4 2025, with the low at -$7.7 million in Q3 2023.
  • Average Change in Account Payables over 5 years is $562700.0, with a median of $743000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 2152.63% in 2023, while the deepest fall reached 374.51% in 2023.
  • Over 5 years, Change in Account Payables stood at $2.4 million in 2021, then plummeted by 68.74% to $750000.0 in 2022, then surged by 425.47% to $3.9 million in 2023, then tumbled by 63.56% to $1.4 million in 2024, then soared by 384.61% to $7.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $7.0 million, $3.5 million, and -$2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.